Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus Erlotinib vs Placebo plus Erlotinib in First-Line MET-Positive EGFR-Mutated Advanced NSCLC
jRCT2080222323Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Onartuzumab + Erlotinib with Placebo + Erlotinib (2 arms).
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222323.